Furthering progress in Translational Medicine – moving from bench to bedside to turn breakthrough research discoveries into healthcare solutions – InnaVirVax is proud to collaborate with leading academic institutions.
Invest for the future
InnaVirVax continuously expands its network with the primary objectives of accessing external resources, incorporating expertise and knowledge so as to optimize time to market and continuously improving its pipeline.
Patients are at the core of our research to improve their quality of life.
InnaVirVax is a privately-owned clinical stage biotechnology company developing cutting-edge, immune-based treatments for infectious and major chronic diseases. These therapies are based on a versatile platform to enable the development of targeted vaccines.
Fund raising operation through the Pre-IPO platform
FDA authorization for a Phase 2 in HIV Functional Cure in the US
InnaVirVax attended CROI 2016
InnaVirVax selected for the last stage of the BigBooster program
InnaVirVax will be at 15th Annual Biotech Congress organized by Sachs Associates the 29th & 30th September
InnaVirVax participated in the conference International AIDS Society in Vancouver, Canada